{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:37Z","timestamp":1786119337662,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8,15]]},"DOI":"10.1097\/tp.0b013e3181af1df6","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T03:34:04Z","timestamp":1249356844000},"page":"421-428","source":"Crossref","is-referenced-by-count":54,"title":["Minimization of Maintenance Immunosuppression Early After Renal Transplantation: An Interim Analysis"],"prefix":"10.1097","volume":"88","author":[{"given":"Frederike J.","family":"Bemelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltjo F.","family":"de Maar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier R.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrikus J.","family":"van Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineke J.","family":"ten Berge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J.","family":"Homan van der Heide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20210211","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0952-7915(98)80215-X","article-title":"The use of antibodies against the IL-2 receptor in transplantation.","volume":"10","author":"Waldmann","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"R2-22-20210211","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","article-title":"Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am J Transplant"},{"key":"R3-22-20210211","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00041552-199811000-00001","article-title":"Pathogenesis of chronic allograft nephropathy.","volume":"7","author":"Paul","year":"1998","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R4-22-20210211","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.semnephrol.2007.03.004","article-title":"Chronic allograft nephropathy.","volume":"27","author":"Vadivel","year":"2007","journal-title":"Semin Nephrol"},{"key":"R5-22-20210211","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.trim.2006.10.001","article-title":"The aetiology and pathogenesis of chronic allograft nephropathy.","volume":"16","author":"Yates","year":"2006","journal-title":"Transpl Immunol"},{"key":"R6-22-20210211","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2215\/CJN.04131206","article-title":"The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs.","volume":"2","author":"Nogueira","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-22-20210211","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.semnephrol.2007.03.005","article-title":"Cardiovascular disease posttransplant.","volume":"27","author":"Pham","year":"2007","journal-title":"Semin Nephrol"},{"key":"R8-22-20210211","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1097\/01.ASN.0000126194.77004.9B","article-title":"Malignancy in renal transplantation.","volume":"15","author":"Morath","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R9-22-20210211","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1034\/j.1600-6143.2003.30112.x","article-title":"Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection.","volume":"3","author":"Meier-Kriesche","year":"2003","journal-title":"Am J Transplant"},{"key":"R10-22-20210211","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"R11-22-20210211","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","article-title":"A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.","volume":"61","year":"1996","journal-title":"Transplantation"},{"key":"R12-22-20210211","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0966-3274(95)80021-2","article-title":"Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts.","volume":"3","author":"R\u00e4is\u00e4nen-Sokolowski","year":"1995","journal-title":"Transpl Immunol"},{"key":"R13-22-20210211","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0021-9150(99)00458-X","article-title":"Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit.","volume":"152","author":"Romero","year":"2000","journal-title":"Atherosclerosis"},{"key":"R14-22-20210211","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00003495-200666040-00009","article-title":"Everolimus: A review of its use in renal and cardiac transplantation.","volume":"66","author":"Dunn","year":"2006","journal-title":"Drugs"},{"key":"R15-22-20210211","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00007691-199512000-00019","article-title":"Rapamune (sirolimus, rapamycin): An overview and mechanism of action.","volume":"17","author":"Sehgal","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R16-22-20210211","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/01.TP.0000074722.79186.A9","article-title":"Apoptosis and treatment of chronic allograft nephropathy with everolimus.","volume":"76","author":"Lutz","year":"2003","journal-title":"Transplantation"},{"key":"R17-22-20210211","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood.V98.1.174","article-title":"Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages.","volume":"98","author":"Woltman","year":"2001","journal-title":"Blood"},{"key":"R18-22-20210211","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2004-09-3540","article-title":"Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.","volume":"105","author":"Guba","year":"2005","journal-title":"Blood"},{"key":"R19-22-20210211","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/00007890-200205270-00008","article-title":"Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy.","volume":"73","author":"Luan","year":"2002","journal-title":"Transplantation"},{"key":"R20-22-20210211","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"R21-22-20210211","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.TP.0000128610.93598.80","article-title":"Differential effects of everolimus and cyclosporine A on intimal alpha-actin-positive cell dynamics of carotid allografts in mice.","volume":"78","author":"Matsumoto","year":"2004","journal-title":"Transplantation"},{"key":"R22-22-20210211","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group.","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"R23-22-20210211","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"R24-22-20210211","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1681\/ASN.2005030249","article-title":"No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.","volume":"17","author":"Rowshani","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R25-22-20210211","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1097\/00007890-200212150-00013","article-title":"Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.","volume":"74","author":"Gonwa","year":"2002","journal-title":"Transplantation"},{"key":"R26-22-20210211","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.TP.0000074360.62032.39","article-title":"Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.","volume":"76","author":"Oberbauer","year":"2003","journal-title":"Transplantation"},{"key":"R27-22-20210211","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.transproceed.2007.07.071","article-title":"Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: Preliminary results of the EVERODATA registry.","volume":"39","author":"Ruiz","year":"2007","journal-title":"Transplant Proc"},{"key":"R28-22-20210211","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1432-2277.2004.00052.x","article-title":"Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.","volume":"18","author":"Oberbauer","year":"2005","journal-title":"Transpl Int"},{"key":"R29-22-20210211","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/00007890-200212270-00015","article-title":"Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study.","volume":"74","author":"Abramowicz","year":"2002","journal-title":"Transplantation"},{"key":"R30-22-20210211","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","article-title":"Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study.","volume":"7","author":"Ekberg","year":"2007","journal-title":"Am J Transplant"},{"key":"R31-22-20210211","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1681\/ASN.2005030312","article-title":"Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial.","volume":"16","author":"Hazzan","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R32-22-20210211","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1681\/ASN.V132536","article-title":"Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen.","volume":"13","author":"Schnuelle","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R33-22-20210211","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/01.ASN.0000013298.11876.BF","article-title":"Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study.","volume":"13","author":"Smak Gregoor","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R34-22-20210211","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1399-0012.2004.00318.x","article-title":"Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.","volume":"19","author":"Arns","year":"2005","journal-title":"Clin Transplant"},{"key":"R35-22-20210211","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/ndt\/gfg065","article-title":"A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients.","volume":"18","author":"Cremers","year":"2003","journal-title":"Nephrol Dial Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0b013e3181af1df6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:00:54Z","timestamp":1786039254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200908150-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,15]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3181af1df6","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8,15]]}}}